AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8735863
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP), 800 micrograms daily
Trial: 1426202
Drug: Bronchodilator therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator therapy alone (salbutamol or ipratropium bromide)
Trial: 30295170
Drug: Satisfaction with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satisfaction with daily activities
Trial: 30295170
Drug: Participation in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participation in daily activities
Trial: 26381427
Drug: aprepitant, extended-duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aprepitant, extended-duration dexamethasone and low-dose olanzapine (high-risk patients)
Trial: 26381427
Drug: extended-duration dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: extended-duration dexamethasone and low-dose olanzapine (high-risk patients)
Trial: 25038148
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) infusion during dynamic handgrip exercise (15% maximal effort)
Trial: 25038148
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) infusion
Trial: 19588075
Drug: Bleaching treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleaching treatment with a plasma arc lamp (Remewhite, Remedent)
Trial: 7503851
Drug: Ketorolac 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 1.0 mg/kg
Trial: 7025778
Drug: Probucol (N
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (N = 61, continued therapy in open trial)
Trial: 21442459
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (once-yearly intravenous dose)
Trial: 21442459
Drug: Alendronate (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (once-weekly oral dose)
Trial: 14686964
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg candesartan cilexetil
Trial: 11848327
Drug: Cyclosporine-A (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine-A (6 mg/kg body weight in divided doses for six months)
Trial: 11848327
Drug: Stanozolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stanozolol (1 mg/kg body weight/day in divided doses)
Trial: 9166392
Drug: HRT (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (2 mg estradiol valerate and 1 mg cyproterone acetate)
Trial: 3391874
Drug: Unprotected EA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unprotected EA tablets
Trial: 3391874
Drug: Acid-protected tablets
RxNorm normalized name: ALLANTOIN 5 mg in 1 g TOPICAL CREAM [Shelo NABEL CACAO Skin Protectan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid-protected tablets
Trial: 3391874
Drug: Unprotected tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unprotected tablet
Trial: 3391874
Drug: Protected tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protected tablet
Trial: 3391874
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg acid-protected tablets
Trial: 3391874
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg acid-protected tablets
Trial: 30599425
Drug: IV dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV dexamethasone (14 mg tapered over 3 days)
Trial: 30599425
Drug: Intensive glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose control (target 80–110 mg·dL−1)
Trial: 30599425
Drug: Conventional glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucose control (target 180–200 mg·dL−1)
Trial: 25936640
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of MPH
Trial: 25936640
Drug: Continuous MPH
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous MPH administration
Trial: 23714959
Drug: Guiding elastic
RxNorm normalized name: elastin
DrugBank: Elastin (human) (DB15364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guiding elastic therapy (arch bar and elastics without rigid intermaxillary fixation for 7 to 12 days)
Trial: 8576810
Drug: L-carnitine supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplemented lipid emulsion
Trial: 999987
Drug: Naltrexone (40-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (40-200 mg per day)
Trial: 30531488
Drug: Nitrate-rich (NR)
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich (NR) supplement
Trial: 30531488
Drug: Nitrate-poor (NP)
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-poor (NP) supplement
Trial: 23632723
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of quadrivalent HPV vaccine at 0 and 6 months (n = 259)
Trial: 23632723
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of quadrivalent HPV vaccine at 0, 2, and 6 months (n = 261 for girls, n = 310 for young women)
Trial: 21196672
Drug: 0.07 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg/kg ephedrine
Trial: 21196672
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg ephedrine
Trial: 21196672
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg ephedrine
Trial: 21196672
Drug: 1.5 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 μg/kg phenylephrine
Trial: 18059067
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy (MET) group programme, 4 sessions in addition to routine hospital care
Trial: 17156590
Drug: Information about
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information about physical exercise after one cycle of cytotoxic drugs
Trial: 17156590
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (information about physical exercise after two cycles of cytotoxic drugs)
Trial: 10460951
Drug: Alpha-1-proteinase inhibitor
RxNorm normalized name: alpha-1-proteinase inhibitor
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-1-proteinase inhibitor (A1PI) supplementation at 60 mg/kg on days 0, 4, 7, and 14
Trial: 8549573
Drug: Drink A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink A (2 mmol.l‐1 sodium)
Trial: 8549573
Drug: Drink B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink B (26 mmol.l‐1 sodium)
Trial: 8549573
Drug: Drink C
RxNorm normalized name: Boost Energy Drink Chocolate Raspberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink C (52 mmol.l‐1 sodium)
Trial: 8549573
Drug: Drink D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink D (100 mmol.l‐1 sodium)
Trial: 27449714
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (30 mg/kg) infused intravenously 15 minutes before tourniquet inflation
Trial: 27449714
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (30 mg/kg) infused intravenously 15 minutes after tourniquet inflation
Trial: 27449714
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (30 mg/kg) infused intravenously on tourniquet deflation
Trial: 27449714
Drug: No tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No tranexamic acid administration
Trial: 17365917
Drug: Lansoprazole (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (60 mg/day) + Amoxicillin (750 mg/day) + Clarithromycin (400 mg/day) for 7 days
Trial: 17365917
Drug: Lansoprazole (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (60 mg/day) + Clarithromycin (400 mg/day) for 7 days
Trial: 9862244
Drug: CGP 56697
RxNorm normalized name: Leucoflex CGP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGP 56697 (artemether 20 mg + benflumetol 120 mg) 4 x 4 tablets over 48 h
Trial: 9862244
Drug: CGP 56697
RxNorm normalized name: Leucoflex CGP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGP 56697 (artemether 20 mg + benflumetol 120 mg) 4 x 2 tablets over 48 h
Trial: 9862244
Drug: CGP 56697
RxNorm normalized name: Leucoflex CGP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGP 56697 (artemether 20 mg + benflumetol 120 mg) 3 x 4 tablets over 24 h
Trial: 2618634
Drug: One-stage treatment
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage treatment
Trial: 24493296
Drug: Two-stage treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-stage treatment
Trial: 35192
Drug: Clobazam 30
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clobazam 30 mg
Trial: 35192
Drug: Dipotassium clorazepate
RxNorm normalized name: Dipotassium clorazepate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipotassium clorazepate 15 mg
Trial: 31900758
Drug: High CRP
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High CRP levels (> 3 mg/L)
Trial: 31447131
Drug: Niacin-laropiprant (2000/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin-laropiprant (2000/40 mg/d)
Trial: 26179616
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplement with added micronutrients
Trial: 26179616
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplement without added micronutrients
Trial: 23354657
Drug: Topical hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hemoglobin solution added to standard wound care
Trial: 21859640
Drug: Mucosolvin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucosolvin (15 mg/kg per day)
Trial: 21859640
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no respiratory drug)
Trial: 16437139
Drug: Sequential ATRA
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential ATRA and chemotherapy
Trial: 16437139
Drug: Pre-therapy detection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-therapy detection
Trial: 16437139
Drug: Subsequent ATRA
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subsequent ATRA therapy
Trial: 12579384
Drug: Lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 8 mg i.v. preoperatively followed by 8 mg every 8 h for a total of 24 mg in the first 24 h
Trial: 12579384
Drug: Lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 8 mg i.v. bolus before the end of the operation followed by 8 mg every 8 h for a total of 24 mg in the first 24 h
Trial: 30941063
Drug: Quitlink intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quitlink intervention with peer worker support and referral to the Victorian Quitline for an 8-week cognitive behavioral intervention and nicotine replacement therapy (NRT)
Trial: 21206285
Drug: High-dosage right
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage right unilateral (RUL) ECT
Trial: 21206285
Drug: Moderate-dosage bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dosage bilateral (BL) ECT
Trial: 21206285
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment with VEN + Li
Trial: 21206285
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment with NT + Li
Trial: 19273782
Drug: Bezafibrate therapy
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate therapy (n = 1509)
Trial: 19273782
Drug: Bezafibrate therapy
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate therapy with upper-tertile HDL-C response (>8 mg/dL)
Trial: 19273782
Drug: Bezafibrate therapy
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate therapy with lower-tertile HDL-C response (<=8 mg/dL)
Trial: 19273782
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (n = 1517)
Trial: 17970879
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate 300 mg q.i.d., lansoprazole 30 mg b.i.d., tetracycline 500 mg q.i.d., metronidazole 500 mg t.i.d. (BLTM group) for 14 days
Trial: 17970879
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d. (LAC group) for 14 days
Trial: 11730781
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with artemether and praziquantel
Trial: 7909912
Drug: Propranolol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.1 mg.kg‐1 body weight) administered intravenously after exercise
Trial: 7909912
Drug: No beta‐adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta‐adrenoceptor blocker administered
Trial: 7909912
Drug: Propranolol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol administered during recovery from exercise
Trial: 2885802
Drug: Erythromycin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (50 mg/kg/day divided in 2 doses for 10 days)
Trial: 28945992
Drug: 2000 U
RxNorm normalized name: lipase 2000 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 U of cholecalciferol daily for 4 months
Trial: 25759545
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg/d orally
Trial: 25759545
Drug: LAM plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM plus ADV (LAM 100 mg/d orally + ADV 10 mg/d orally)
Trial: 21094030
Drug: Aspirin (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (50mg per day) and sanchitongshu capsule (200mg three times a day)
Trial: 21094030
Drug: Aspirin (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (50mg per day) and placebo capsule
Trial: 19127598
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone supplements
Trial: 17455121
Drug: Strength Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength Training (ST: twice a week)
Trial: 14749647
Drug: Sustained-release dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sustained-release dinoprostone with concurrent low-dose oxytocin
Trial: 14749647
Drug: Multidosing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidosing of misoprostol (25 microg every 4 hours) followed by high-dose oxytocin
Trial: 12197993
Drug: Beef-containing (BC)
RxNorm normalized name: Beef
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beef-containing (BC) diet, n = 10, 0.6 g protein.kg(‐1).d(‐1) from beef
Trial: 12197993
Drug: Lactoovovegetarian (LOV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoovovegetarian (LOV) diet, n = 11, 0.6 g protein.kg(‐1).d(‐1) from textured vegetable protein (soy) sources
Trial: 10220834
Drug: High titers
RxNorm normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High titers of anti-IL-8 antibody subclasses and complexes
Trial: 2203181
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg natamycin by nebuliser twice daily for one year
Trial: 2203181
Drug: Placebo by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by nebuliser twice daily for one year
Trial: 28425312
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of PNU-120596 (8 µg/kg, 15 min before surgery)
Trial: 28425312
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of PNU-120596
Trial: 28425312
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of K+‐Cl‐ cotransporter‐2 inhibitor VU0240551
Trial: 25824475
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) performed three times a week
Trial: 15493396
Drug: Valacyclovir (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir (2 grams taken twice on the day of dental treatment and 1 g taken twice the next day)
Trial: 11189690
Drug: Quality control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality control procedures for cancer screening tests (digital rectal examination, ovarian palpation examination, transvaginal ultrasound, chest X-ray, flexible sigmoidoscopy)
Trial: 9194104
Drug: Cefpodoxime-proxetil or
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime-proxetil or Amoxicillin-clavulanate
Trial: 1347336
Drug: M‐CH (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M‐CH (50 mg mitomycin intraoperatively)
Trial: 3912787
Drug: Progressive relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive relaxation therapy during a 3-week interval
Trial: 3912787
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment followed by progressive relaxation therapy
Trial: 24233255
Drug: Prebiotics enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotics enriched formula containing dietary oligosaccharides (scGOS/lcFOS) at a concentration of 0.8 g/100 ml
Trial: 22660441
Drug: Fimasartan (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan (single dose)
Trial: 22660441
Drug: Fimasartan (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan (daily for 30 days)
Trial: 20030830
Drug: Exercise tolerance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise tolerance testing followed by coronary angiography and treatment (percutaneous stenting or surgery) if positive results are found.
Trial: 20030830
Drug: Best medical/behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical/behavioral therapy offered to the exercise testing group.
Trial: 20030830
Drug: Best medical/behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical/behavioral therapy offered to the control group (regular follow-up at diabetes outpatient services).
Trial: 9455667
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (segmental fusion)
Trial: 2646131
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of enuresis alarm and 20 micrograms intranasal desmopressin
Trial: 28372680
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia (intrathecal 0.5% hyperbaric bupivacaine 12.5 mg and 25 μg fentanyl)
Trial: 28372680
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (intravenous analgesia, propofol, and rocuronium followed by endotracheal intubation)
Trial: 23271674
Drug: Immediate empirical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate empirical therapy with voriconazole
Trial: 23271674
Drug: Deferred therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred therapy (placebo)
Trial: 17926205
Drug: Non‐anaesthetic gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐anaesthetic gel
Trial: 17926205
Drug: Anaesthetic gel
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaesthetic gel (Instillagel)